Background
Methods
Study design
Data sources for IBD
Data sources for cancer
MR analysis
Results
Genetic instruments and strength
Discovery results of cancer risk
Phenotypes | ORIVW (95% CI) | PIVW | Pheterogeneity | Ppleiotropy |
---|---|---|---|---|
Respiratory system | ||||
Larynx | 0.929 (0.789, 1.094) | 0.380 | 0.008 | 0.006 |
Bronchus and lung | 1.005 (0.956, 1.055) | 0.853 | 0.029 | 0.028 |
Oral cavity and pharynx | ||||
Oral cavity | 1.180 (1.059, 1.316) | 0.003 | 0.134 | 0.137 |
Pharynx | 1.011 (0.909, 1.125) | 0.836 | 0.724 | 0.722 |
Digestive system cancer | ||||
Esophagus | 0.960 (0.888, 1.038) | 0.303 | 0.923 | 0.928 |
Small intestine | 1.043 (0.888, 1.226) | 0.607 | 0.213 | 0.193 |
Stomach | 0.961 (0.880, 1.049) | 0.368 | 0.868 | 0.872 |
Pancreas | 1.001 (0.921, 1.087) | 0.988 | 0.221 | 0.242 |
Hepatocellular | 0.923 (0.743, 1.148) | 0.473 | 0.406 | 0.404 |
Hepatic bile duct | 1.082 (0.849, 1.379) | 0.546 | 0.250 | 0.271 |
Extrahepatic bile duct | 0.919 (0.775, 1.090) | 0.332 | 0.496 | 0.500 |
Hematologic malignancy | ||||
Multiple myeloma | 0.938 (0.851, 1.035) | 0.203 | 0.018 | 0.019 |
Hodgkin lymphoma | 0.978 (0.850, 1.126) | 0.761 | 0.423 | 0.406 |
Non-Hodgkin lymphoma | 1.029 (0.969, 1.093) | 0.343 | < 0.001 | 0.001 |
Acute myelocytic leukemia | 0.908 (0.801, 1.029) | 0.130 | 0.195 | 0.204 |
Chronic myeloid leukemia | 0.839 (0.696, 1.012) | 0.067 | 0.392 | 0.425 |
Chronic lymphocytic leukemia | 1.003 (0.899, 1.120) | 0.952 | 0.002 | 0.003 |
Genital system | ||||
Ovary | 0.970 (0.903, 1.042) | 0.411 | 0.714 | 0.700 |
Uterine cervix | 1.050 (0.900, 1.225) | 0.536 | 0.146 | 0.168 |
Uterine corpus | 1.006 (0.938, 1.079) | 0.867 | 0.041 | 0.032 |
Vulva | 0.991 (0.801, 1.224) | 0.930 | 0.469 | 0.468 |
Testis | 1.028 (0.914, 1.156) | 0.644 | 0.999 | 0.997 |
Prostate | 1.008 (0.974, 1.044) | 0.651 | < 0.001 | < 0.001 |
Breast | 1.045 (1.005, 1.086) | 0.043 | 0.878 | 0.901 |
Skin cancer | ||||
Malignant melanoma | 1.004 (0.954, 1.057) | 0.871 | 0.074 | 0.051 |
Malignant nonmelanoma | 1.030 (0.995, 1.067) | 0.099 | < 0.001 | < 0.001 |
Other | ||||
Eye and annexa | 1.146 (0.968, 1.356) | 0.115 | 0.483 | 0.478 |
Kidney | 1.013 (0.947, 1.084) | 0.701 | 0.482 | 0.478 |
Bladder | 0.994 (0.944, 1.047) | 0.821 | 0.106 | 0.098 |
Bone | 1.025 (0.852, 1.232) | 0.794 | 0.999 | 0.998 |
Brain | 1.104 (1.003, 1.216) | 0.043 | 0.336 | 0.350 |
Thyroid | 0.976 (0.868, 1.097) | 0.683 | 0.955 | 0.953 |
Phenotypes | Crohn’s disease | Ulcerative colitis | ||||||
---|---|---|---|---|---|---|---|---|
ORIVW (95% CI) | PIVW | Pheterogeneity | Ppleiotropy | ORIVW (95% CI) | PIVW | Pheterogeneity | Ppleiotropy | |
Respiratory system | ||||||||
Larynx | 0.928 (0.799, 1.077) | 0.090 | 0.046 | 0.051 | 1.025 (0.861, 1.220) | 0.779 | 0.064 | 0.062 |
Bronchus and lung | 0.997 (0.954, 1.042) | 0.900 | 0.012 | 0.013 | 1.036 (0.985, 1.090) | 0.167 | 0.270 | 0.281 |
Oral cavity and pharynx | ||||||||
Oral cavity | 1.112 (1.008, 1.227) | 0.034 | 0.111 | 0.135 | 1.158 (1.041, 1.288) | 0.007 | 0.487 | 0.455 |
Pharynx | 1.019 (0.927, 1.121) | 0.696 | 0.847 | 0.840 | 1.035 (0.924, 1.159) | 0.553 | 0.371 | 0.367 |
Digestive system cancer | ||||||||
Esophagus | 0.982 (0.917, 1.050) | 0.589 | 0.506 | 0.502 | 0.986 (0.906, 1.074) | 0.752 | 0.973 | 0.973 |
Small intestine | 1.037 (0.892, 1.205) | 0.640 | 0.018 | 0.015 | 1.124 (0.949, 1.332) | 0.175 | 0.486 | 0.490 |
Stomach | 0.997 (0.924, 1.076) | 0.939 | 0.507 | 0.488 | 0.951 (0.864, 1.046) | 0.303 | 0.590 | 0.591 |
Pancreas | 0.977 (0.910, 1.047) | 0.506 | 0.360 | 0.359 | 1.020 (0.932, 1.116) | 0.671 | 0.272 | 0.257 |
Hepatocellular | 0.949 (0.785, 1.147) | 0.586 | 0.387 | 0.366 | 0.908 (0.714, 1.155) | 0.432 | 0.289 | 0.302 |
Hepatic bile duct | 1.170 (0.948, 1.444) | 0.144 | 0.257 | 0.285 | 1.020 (0.792, 1.313) | 0.879 | 0.634 | 0.668 |
Extrahepatic bile duct | 0.964 (0.831, 1.118) | 0.626 | 0.687 | 0.672 | 0.928 (0.772, 1.116) | 0.428 | 0.792 | 0.774 |
Hematologic malignancy | ||||||||
Multiple myeloma | 0.969 (0.894, 1.051) | 0.449 | 0.137 | 0.141 | 0.983 (0.885, 1.091) | 0.749 | 0.094 | 0.102 |
Hodgkin lymphoma | 0.990 (0.877, 1.117) | 0.867 | 0.669 | 0.673 | 0.965 (0.820, 1.136) | 0.672 | 0.154 | 0.175 |
Non-Hodgkin lymphoma | 1.010 (0.958, 1.065) | 0.709 | < 0.001 | < 0.001 | 1.058 (0.987, 1.134) | 0.110 | < 0.001 | < 0.001 |
Acute myelocytic leukemia | 0.930 (0.838, 1.032) | 0.170 | 0.524 | 0.508 | 0.991 (0.860, 1.142) | 0.899 | 0.115 | 0.117 |
Chronic myeloid leukemia | 0.889 (0.757, 1.043) | 0.149 | 0.624 | 0.633 | 0.921 (0.747, 1.134) | 0.438 | 0.305 | 0.307 |
Chronic lymphocytic leukemia | 0.981 (0.891, 1.080) | 0.697 | 0.004 | 0.006 | 0.967 (0.872, 1.073) | 0.528 | 0.793 | 0.791 |
Genital system | ||||||||
Ovary | 0.951 (0.892, 1.015) | 0.132 | 0.216 | 0.211 | 0.983 (0.909, 1.063) | 0.661 | 0.522 | 0.511 |
Uterine cervix | 1.043 (0.920, 1.184) | 0.510 | 0.545 | 0.546 | 0.978 (0.834, 1.147) | 0.786 | 0.808 | 0.807 |
Uterine corpus | 0.989 (0.928, 1.053) | 0.723 | 0.004 | 0.005 | 0.954 (0.885, 1.028) | 0.216 | 0.114 | 0.105 |
Vulva | 1.142 (0.947, 1.377) | 0.165 | 0.336 | 0.351 | 0.864 (0.673, 1.109) | 0.251 | 0.118 | 0.124 |
Testis | 1.040 (0.939, 1.151) | 0.451 | 0.996 | 0.997 | 0.983 (0.864, 1.117) | 0.790 | 0.998 | 0.999 |
Prostate | 0.998 (0.973, 1.024) | 0.902 | 0.441 | 0.443 | 1.012 (0.973, 1.052) | 0.543 | < 0.001 | 0.001 |
Breast | 1.008 (0.958, 1.061) | 0.691 | 0.980 | 0.961 | 1.013 (0.955, 1.074) | 0.675 | 0.692 | 0.697 |
Skin cancer | ||||||||
Malignant melanoma | 1.024 (0.978, 1.072) | 0.305 | 0.038 | 0.039 | 1.009 (0.953, 1.069) | 0.749 | 0.087 | 0.084 |
Malignant nonmelanoma | 1.041 (1.009, 1.075) | 0.012 | < 0.001 | < 0.001 | 1.012 (0.985, 1.039) | 0.392 | < 0.001 | < 0.001 |
Other | ||||||||
Eye and annexa | 1.120 (0.978, 1.296) | 0.129 | 0.561 | 0.564 | 1.092 (0.908, 1.312) | 0.350 | 0.557 | 0.556 |
Kidney | 1.033 (0.975, 1.095) | 0.274 | 0.500 | 0.510 | 1.011 (0.937, 1.092) | 0.773 | 0.234 | 0.250 |
Bladder | 1.008 (0.965, 1.053) | 0.724 | 0.214 | 0.211 | 0.979 (0.925, 1.035) | 0.453 | 0.151 | 0.160 |
Bone | 1.062 (0.905, 1.245) | 0.460 | 0.978 | 0.987 | 0.900 (0.736, 1.100) | 0.304 | 0.910 | 0.908 |
Brain | 1.105 (1.013, 1.205) | 0.024 | 0.124 | 0.144 | 1.081 (0.975, 1.198) | 0.137 | 0.490 | 0.474 |
Thyroid | 1.005 (0.907, 1.112) | 0.930 | 0.713 | 0.736 | 0.958 (0.841, 1.091) | 0.514 | 0.403 | 0.413 |
Replication results of cancer risk
Combined results of cancer risk from the meta-analysis
Final causality of cancer risk
Phenotypes | Inflammatory bowel disease | Crohn’s disease | Ulcerative colitis | ||||||
---|---|---|---|---|---|---|---|---|---|
Data sources | OR (95% CI) | P | Data sources | OR (95% CI) | P | Data sources | OR (95% CI) | P | |
Respiratory system | |||||||||
Larynx | UKB + FinnGen | 0.904 (0.813, 1.005) | 0.062 | UKB + FinnGen | 0.915 (0.833, 1.006) | 0.067 | UKB + FinnGen | 0.960 (0.859, 1.072) | 0.469 |
Bronchus and lung | UKB + FinnGen + ILCCO | 1.008 (0.984, 1.033) | 0.504 | UKB + ILCCO | 1.008 (0.965, 1.053) | 0.729 | UKB + FinnGen + ILCCO | 1.014 (0.989, 1.040) | 0.273 |
Oral cavity and pharynx | |||||||||
Oral cavity | Lesseur, C | 1.180 (1.059, 1.316) | 0.003 | Lesseur, C | 1.112 (1.008, 1.227) | 0.034 | Lesseur, C | 1.158 (1.041, 1.288) | 0.007 |
Pharynx | Lesseur, C | 1.011 (0.909, 1.125) | 0.836 | Lesseur, C | 1.019 (0.927, 1.121) | 0.696 | Lesseur, C | 1.035 (0.924, 1.159) | 0.553 |
Digestive system cancer | |||||||||
Esophagus | UKB + FinnGen | 0.948 (0.889, 1.011) | 0.103 | UKB + FinnGen | 0.969 (0.917, 1.024) | 0.263 | UKB + FinnGen | 0.966 (0.899, 1.037) | 0.335 |
Small intestine | UKB + FinnGen | 0.971 (0.881, 1.071) | 0.556 | UKB + FinnGen | 1.003 (0.921, 1.092) | 0.953 | UKB + FinnGen | 1.009 (0.829, 1.227) | 0.932 |
Stomach | UKB + FinnGen | 1.005 (0.925, 1.092) | 0.912 | UKB + FinnGen | 1.008 (0.960, 1.059) | 0.736 | UKB + FinnGen | 0.993 (0.932, 1.057) | 0.820 |
Pancreas | UKB + FinnGen + PanScan | 1.007 (0.956, 1.060) | 0.797 | UKB + FinnGen + PanScan | 0.992 (0.950, 1.036) | 0.714 | UKB + FinnGen + PanScan | 1.029 (0.971, 1.089) | 0.338 |
Hepatocellular | UKB | 0.923 (0.743, 1.148) | 0.473 | UKB | 0.949 (0.785, 1.147) | 0.586 | UKB | 0.908 (0.714, 1.156) | 0.432 |
Hepatic bile duct | UKB | 1.082 (0.849, 1.379) | 0.546 | UKB | 1.170 (0.948, 1.444) | 0.144 | UKB | 1.020 (0.792, 1.313) | 0.879 |
Extrahepatic bile duct | UKB | 0.919 (0.775, 1.090) | 0.332 | UKB | 0.964 (0.831, 1.118) | 0.626 | UKB | 0.928 (0.772, 1.116) | 0.428 |
Hematologic malignancy | |||||||||
Multiple myeloma | UKB + FinnGen | 1.012 (0.886, 1.155) | 0.863 | UKB + FinnGen | 1.030 (0.919, 1.155) | 0.611 | UKB + FinnGen | 1.029 (0.963, 1.100) | 0.398 |
Hodgkin lymphoma | UKB + FinnGen | 1.005 (0.927, 1.090) | 0.897 | UKB + FinnGen | 1.013 (0.943, 1.088) | 0.729 | UKB + FinnGen | 1.004 (0.916, 1.101) | 0.932 |
Non-Hodgkin lymphoma | UKB | 1.007 (0.954, 1.064) | 0.796 | UKB | 0.997 (0.950, 1.047) | 0.914 | UKB | 1.027 (0.967, 1.092) | 0.385 |
Acute myelocytic leukemia | UKB + FinnGen | 0.978 (0.821, 1.164) | 0.799 | UKB + FinnGen | 1.035 (0.819, 1.308) | 0.775 | UKB + FinnGen | 1.014 (0.903, 1.139) | 0.814 |
Chronic myeloid leukemia | UKB + FinnGen | 0.926 (0.733, 1.169) | 0.517 | UKB + FinnGen | 0.907 (0.795, 1.036) | 0.150 | UKB + FinnGen | 0.902 (0.760, 1.071) | 0.240 |
Chronic lymphocytic leukemia | UKB + FinnGen | 1.022 (0.945, 1.106) | 0.581 | UKB + FinnGen | 0.988 (0.924, 1.057) | 0.734 | UKB + FinnGen | 1.022 (0.905, 1.153) | 0.728 |
Genital system | |||||||||
Ovary | UKB + FinnGen + OCAC | 0.993 (0.971, 1.015) | 0.535 | UKB + FinnGen + OCAC | 1.004 (0.986, 1.023) | 0.646 | UKB + FinnGen + OCAC | 0.983 (0.961, 1.006) | 0.148 |
Uterine cervix | UKB + FinnGen | 1.027 (0.980, 1.075) | 0.265 | UKB + FinnGen | 1.031 (0.991, 1.072) | 0.132 | UKB + FinnGen | 1.017 (0.987, 1.048) | 0.258 |
Uterine corpus | UKB + FinnGen + O’Mara et.al | 0.982 (0.959, 1.006) | 0.140 | FinnGen + O’Mara et.al | 0.994 (0.972, 1.017) | 0.598 | UKB + FinnGen + O’Mara et.al | 0.986 (0.961, 1.012) | 0.292 |
Vulva | UKB + FinnGen | 0.995 (0.871, 1.136) | 0.940 | UKB + FinnGen | 1.011 (0.806, 1.267) | 0.926 | UKB + FinnGen | 0.904 (0.779, 1.050) | 0.187 |
Testis | UKB + FinnGen | 0.976 (0.892, 1.068) | 0.600 | UKB + FinnGen | 1.014 (0.938, 1.097) | 0.727 | UKB + FinnGen | 0.996 (0.902, 1.101) | 0.944 |
Prostate | UKB + FinnGen | 1.010 (0.988, 1.032) | 0.380 | UKB + FinnGen | 1.003 (0.983, 1.018) | 0.972 | UKB + FinnGen | 1.020 (0.997, 1.045) | 0.090 |
Breast | UKB + BCAC | 1.059 (1.033, 1.086) | < 0.0001 | UKB + BCAC | 1.029 (1.002, 1.055) | 0.032 | UKB + FinnGen + BCAC | 1.016 (0.981, 1.053) | 0.372 |
Skin cancer | |||||||||
Malignant melanoma | UKB + FinnGen | 1.030 (0.994, 1.068) | 0.105 | UKB + FinnGen | 1.021 (0.990, 1.053) | 0.183 | UKB + FinnGen | 1.042 (0.979, 1.110) | 0.196 |
Malignant nonmelanoma | None | / | / | None | / | / | None | / | / |
Other | |||||||||
Eye and annexa | UKB + FinnGen | 1.098 (0.967, 1.246) | 0.150 | UKB + FinnGen | 1.073 (0.961, 1.198) | 0.212 | UKB + FinnGen | 1.018 (0.886, 1.170) | 0.804 |
Kidney | UKB + FinnGen + IARC | 0.995 (0.962, 1.030) | 0.791 | UKB + FinnGen + IARC | 1.022 (0.970, 1.077) | 0.417 | UKB + FinnGen + IARC | 0.983 (0.946, 1.021) | 0.366 |
Bladder | UKB + FinnGen | 0.993 (0.956, 1.031) | 0.703 | UKB + FinnGen | 1.004 (0.972, 1.037) | 0.799 | UKB + FinnGen | 0.986 (0.945, 1.028) | 0.502 |
Bone | UKB + FinnGen | 1.050 (0.918, 1.201) | 0.475 | UKB + FinnGen | 1.005 (0.899, 1.124) | 0.930 | UKB + FinnGen | 0.958 (0.826, 1.111) | 0.572 |
Brain | UKB + FinnGen | 1.043 (0.935, 1.163) | 0.448 | UKB + FinnGen | 1.064 (0.992, 1.127) | 0.067 | UKB + FinnGen | 1.039 (0.969, 1.114) | 0.285 |
Thyroid | UKB + FinnGen + Kohler A et.al | 1.018 (0.960, 1.081) | 0.548 | UKB + FinnGen + Kohler A et.al | 1.023 (0.975, 1.074) | 0.358 | UKB + FinnGen + Kohler A et.al | 0.990 (0.927, 1.057) | 0.768 |